Mammalian TRP Ion Channels Are Insensitive to Membrane Stretch Yury A
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Natural Product Modulators of Transient Receptor Potential (TRP) Channels As Potential Cite This: Chem
Chem Soc Rev View Article Online TUTORIAL REVIEW View Journal | View Issue Natural product modulators of transient receptor potential (TRP) channels as potential Cite this: Chem. Soc. Rev., 2016, 45,6130 anti-cancer agents Tiago Rodrigues,a Florian Sieglitza and Gonçalo J. L. Bernardes*ab Treatment of cancer is a significant challenge in clinical medicine, and its research is a top priority in chemical biology and drug discovery. Consequently, there is an urgent need for identifying innovative chemotypes capable of modulating unexploited drug targets. The transient receptor potential (TRPs) channels persist scarcely explored as targets, despite intervening in a plethora of pathophysiological events in numerous diseases, including cancer. Both agonists and antagonists have proven capable of evoking phenotype changes leading to either cell death or reduced cell migration. Among these, natural products entail biologically pre-validated and privileged architectures for TRP recognition. Furthermore, several natural products have significantly contributed to our current knowledge on TRP biology. In this Creative Commons Attribution 3.0 Unported Licence. Tutorial Review we focus on selected natural products, e.g. capsaicinoids, cannabinoids and terpenes, by highlighting challenges and opportunities in their use as starting points for designing natural product- Received 17th December 2015 inspired TRP channel modulators. Importantly, the de-orphanization of natural products as TRP channel DOI: 10.1039/c5cs00916b ligands may leverage their exploration as viable strategy for developing anticancer therapies. Finally, we foresee that TRP channels may be explored for the selective pharmacodelivery of cytotoxic payloads to www.rsc.org/chemsocrev diseased tissues, providing an innovative platform in chemical biology and molecular medicine. -
The Structural Basis for an On–Off Switch Controlling Gβγ-Mediated Inhibition of TRPM3 Channels
The structural basis for an on–off switch controlling Gβγ-mediated inhibition of TRPM3 channels Marc Behrendta,b,1,2, Fabian Grussc,1,3, Raissa Enzerotha,b, Sandeep Demblaa,b, Siyuan Zhaod, Pierre-Antoine Crassousd, Florian Mohra, Mieke Nysc, Nikolaos Lourose, Rodrigo Gallardoe,4, Valentina Zorzinif,5, Doris Wagnera, Anastassios Economou (Αναστάσιoς Οικoνόμoυ)f, Frederic Rousseaue, Joost Schymkowitze, Stephan E. Philippg, Tibor Rohacsd, Chris Ulensc,6, and Johannes Oberwinklera,b,6 aInstitut für Physiologie und Pathophysiologie, Philipps-Universität Marburg, 35037 Marburg, Germany;bCenter for Mind, Brain and Behavior (CMBB), Philipps-Universität Marburg and Justus-Liebig-Universität Giessen, 35032 Marburg, Germany; cLaboratory of Structural Neurobiology, Department of Cellular and Molecular Medicine, KU Leuven, 3000 Leuven, Belgium; dDepartment of Pharmacology, Physiology and Neuroscience, Rutgers New Jersey Medical School, Newark, NJ 07103; eSwitch Laboratory, VIB Center for Brain and Disease Research, Department of Cellular and Molecular Medicine, KU Leuven, 3000 Leuven, Belgium; fLaboratory of Molecular Bacteriology, Department of Microbiology and Immunology, Rega Institute for Medical Research, KU Leuven, 3000 Leuven, Belgium; and gExperimentelle und Klinische Pharmakologie und Toxikologie, Universität des Saarlandes, 66421 Homburg, Germany Edited by László Csanády, Semmelweis University, Budapest, Hungary, and accepted by Editorial Board Member David E. Clapham August 27, 2020 (received for review February 13, 2020) TRPM3 channels play important roles in the detection of noxious also subject to inhibition by activated μORsorotherGPCRs(6, heat and in inflammatory thermal hyperalgesia. The activity of 24–28), a process that has been shown to take place in peripheral these ion channels in somatosensory neurons is tightly regulated by endings of nociceptive neurons since locally applied μOR or μ βγ -opioid receptors through the signaling of G proteins, thereby GABA receptor agonists inhibit TRPM3-dependent pain (24–26). -
The Intracellular Ca2+ Release Channel TRPML1 Regulates Lower Urinary Tract Smooth Muscle Contractility
The intracellular Ca2+ release channel TRPML1 regulates lower urinary tract smooth muscle contractility Caoimhin S. Griffina, Michael G. Alvaradoa, Evan Yamasakia, Bernard T. Drummb,c, Vivek Krishnana, Sher Alia, Eleanor M. Naglea, Kenton M. Sandersb, and Scott Earleya,1 aDepartment of Pharmacology, Center for Molecular and Cellular Signaling in the Cardiovascular System, Reno School of Medicine, University of Nevada, Reno, NV 89557-0318; bDepartment of Physiology and Cell Biology, Reno School of Medicine, University of Nevada, Reno, NV 89557-0318; and cDepartment of Life & Health Sciences, Dundalk Institute of Technology, Louth, Ireland A91 K584 Edited by Mark T. Nelson, University of Vermont, Burlington, VT, and approved October 13, 2020 (received for review August 12, 2020) TRPML1 (transient receptor potential mucolipin 1) is a Ca2+-perme- including dense granulomembranous storage bodies in neurons, able, nonselective cation channel that is predominantly localized to elevated plasma gastrin, vacuolization in the gastric mucosa, and the membranes of late endosomes and lysosomes (LELs). Intracellular retinal degeneration (14). Interestingly, however, an anatomical release of Ca2+ through TRPML1 is thought to be pivotal for mainte- examination of these mice reveals dramatically distended bladders nance of intravesicular acidic pH as well as the maturation, fusion, and (14), leading us to question how TRPML1, an intracellular Ca2+- trafficking of LELs. Interestingly, genetic ablation of TRPML1 in mice release channel important in LEL function, affects bladder −/− (Mcoln1 ) induces a hyperdistended/hypertrophic bladder phenotype. physiology. Here, we investigated this phenomenon further by exploring an un- The lower urinary tract (LUT) is composed of the urinary conventional role for TRPML1 channels in the regulation of Ca2+-signal- bladder and urethra—structures that serve the simple, reciprocal ing activity and contractility in bladder and urethral smooth muscle cells functions of storing and voiding urine (15). -
The TRPP2-Dependent Channel of Renal Primary Cilia Also Requires TRPM3
The TRPP2-dependent channel of renal primary cilia also requires TRPM3 Steven J. Kleene1, Brian J. Siroky2, Julio A. Landero-Figueroa3, Bradley P. Dixon4, Nolan W. Pachciarz2, Lu Lu2, and Nancy K. Kleene1 1Department of Pharmacology and Systems Physiology, University of Cincinnati, Cincinnati, Ohio; 2Division of Nephrology and Hypertension, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio; 3Department of Chemistry, University of Cincinnati, Cincinnati, Ohio; 4Renal Section, Department of Pediatrics, University of Colorado School of Medicine, Aurora, Colorado IntroductIon Primary cilia of renal epithelial cells express several members of the transient receptor potential (TRP) class of cation-conducting channel, including TRPC1, TRPM3, TRPM4, TRPP2, and TRPV4. Some cases of autosomal dominant polycystic kidney disease (ADPKD) are caused by defects in TRPP2 (also called polycystin-2, PC2, or PKD2). A large-conductance, TRPP2- dependent channel in renal cilia has been well described, but it is not known whether this channel includes any other protein subunits. Methods To study this question, we investigated the pharmacology of the TRPP2-dependent channel through electrical recordings from the cilia of mIMCD-3 cells, a murine cell line of renal epithelial origin, results The pharmacology was found to match that of TRPM3 channels. The ciliary TRPP2-dependent channel is known to be activated by depolarization and/or increasing cytoplasmic Ca2+. This activation was greatly enhanced by external pregnenolone sulfate, an agonist of TRPM3 channels. Pregnenolone sulfate did not change the current-voltage relation of the channel. CIM0216, another TRPM3 agonist, modestly increased the activity of the ciliary channels. The channels were effectively blocked by isosakuranetin, a specific inhibitor of TRPM3 channels. -
Recessive Mutations of the Gene TRPM1 Abrogate on Bipolar Cell Function and Cause Complete Congenital Stationary Night Blindness in Humans
View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector REPORT Recessive Mutations of the Gene TRPM1 Abrogate ON Bipolar Cell Function and Cause Complete Congenital Stationary Night Blindness in Humans Zheng Li,1 Panagiotis I. Sergouniotis,1 Michel Michaelides,1,2 Donna S. Mackay,1 Genevieve A. Wright,2 Sophie Devery,2 Anthony T. Moore,1,2 Graham E. Holder,1,2 Anthony G. Robson,1,2 and Andrew R. Webster1,2,* Complete congenital stationary night blindness (cCSNB) is associated with loss of function of rod and cone ON bipolar cells in the mammalian retina. In humans, mutations in NYX and GRM6 have been shown to cause the condition. Through the analysis of a consan- guineous family and screening of nine additional pedigrees, we have identified three families with recessive mutations in the gene TRPM1 encoding transient receptor potential cation channel, subfamily M, member 1, also known as melastatin. A number of other variants of unknown significance were found. All patients had myopia, reduced central vision, nystagmus, and electroretinographic evidence of ON bipolar cell dysfunction. None had abnormalities of skin pigmentation, although other skin conditions were reported. RNA derived from human retina and skin was analyzed and alternate 50 exons were determined. The most 50 exon is likely to harbor an initiation codon, and the protein sequence is highly conserved across vertebrate species. These findings suggest an important role of this specific cation channel for the normal function of ON bipolar cells in the human retina. Congenital stationary night blindness (CSNB) is a group of of the gene encoding transient receptor potential cation genetically determined, nondegenerative disorders of the channel, subfamily M, member 1 (TRPM1 [MIM *603576]) retina associated with lifelong deficient vision in the dark has been discovered in the skin and retina of horses homo- and often nystagmus and myopia. -
TRPC1 Antibody Affinity Purified Polyclonal Antibody Catalog # AG1458
9765 Clairemont Mesa Blvd, Suite C San Diego, CA 92124 Tel: 858.875.1900 Fax: 858.622.0609 TRPC1 Antibody Affinity purified polyclonal antibody Catalog # AG1458 Specification TRPC1 Antibody - Product Information Application WB, IHC Primary Accession P48995 Reactivity Human, Mouse, Rat Host Rabbit Clonality Polyclonal Calculated MW 91212 Homology Mouse, rat, human - identical; rabbit, bovine - 14/15 amino acid residues identical; Western blot analysis of rat brain Xenopus Laevis - membranes: 11/14 amino acid 1. Anti-TRPC1 antibody (#AG1458), (1:200). residues identical. 2. Anti-TRPC1 antibody, preincubated with the control peptide antigen. TRPC1 Antibody - Additional Information Gene ID 7220 Other Names Short transient receptor potential channel 1, TrpC1, Transient receptor protein 1, TRP-1, TRPC1, TRP1 Related products for control experiments Control peptide antigen (supplied with the antibody free of charge). Target/Specificity Peptide QLYDKGYTSKEQKDC, corresponding to amino acid residues 557-571 of human .TRPC1 (Accession P48995).ֲ ֲ Intracellular Expression of TRPC1 in mouse cerebellum Immunohistochemical staining of mouse Dilution WB~~1:200-1:2000 cerebellum frozen sections using Anti-TRPC1 antibody (#AG1458). A. TRPC1 (red) appears in Peptide Confirmation Purkinje cells (arrows) and in the molecular Confirmed by amino acid analysis and (Mol) and granule (Gran) layers. B. Staining massspectrography. with mouse anti-parvalbumin (PV) in the same brain section. C. Confocal merge of TRPC1 and Application Details PV demonstrates partial co-localization in the Western blot analysis (WB): - Mouse brain Purkinje and the molecular layers. lysate (see Feng, S. <em>et al.</em> (2013) in Product Citations). - Rat distal pulmonary smooth muscle cell lysate (PASMCs), (see TRPC1 Antibody - Background Zhang, Y. -
The TRPM4 Channel Inhibitor 9-Phenanthrol
W&M ScholarWorks Arts & Sciences Articles Arts and Sciences 2014 The TRPM4 channel inhibitor 9-phenanthrol R. Guinamard T. Hof C. A. Del Negro College of William and Mary Follow this and additional works at: https://scholarworks.wm.edu/aspubs Recommended Citation Guinamard, R., Hof, T., & Del Negro, C. A. (2014). The TRPM4 channel inhibitor 9‐phenanthrol. British Journal of Pharmacology, 171(7), 1600-1613. This Article is brought to you for free and open access by the Arts and Sciences at W&M ScholarWorks. It has been accepted for inclusion in Arts & Sciences Articles by an authorized administrator of W&M ScholarWorks. For more information, please contact [email protected]. British Journal of DOI:10.1111/bph.12582 www.brjpharmacol.org BJP Pharmacology REVIEW Correspondence Romain Guinamard, Groupe Signalisation, Electrophysiologie et Imagerie des Lésions The TRPM4 channel d’Ischémie/Reperfusion Myocardique, EA4650, Université de Caen Basse Normandie, inhibitor 9-phenanthrol Sciences D, Esplande de la Paix, CS 14032, 14032 Caen Cedex 5, R Guinamard1,2, T Hof1 and C A Del Negro2 France. E-mail: [email protected] ---------------------------------------------------------------- 1EA 4650, Groupe Signalisation, Electrophysiologie et Imagerie des Lésions d’Ischémie-Reperfusion Myocardique, UCBN, Normandie Université, Caen, France, 2Department Keywords 9-phenanthrol; TRPM4; of Applied Science, The College of William and Mary, Williamsburg, VA, USA calcium-activated non-selective cation channel; cardioprotection; NSCCa ---------------------------------------------------------------- Received 1 November 2013 Revised 17 December 2013 Accepted 8 January 2014 The phenanthrene-derivative 9-phenanthrol is a recently identified inhibitor of the transient receptor potential melastatin (TRPM) 4 channel, a Ca2+-activated non-selective cation channel whose mechanism of action remains to be determined. -
Expression of Transient Receptor Potential Channels in the Ependymal Cells of the Developing Rat Brain
Original Article http://dx.doi.org/10.5115/acb.2013.46.1.68 pISSN 2093-3665 eISSN 2093-3673 Expression of transient receptor potential channels in the ependymal cells of the developing rat brain Kwang Deog Jo1, Kyu-Seok Lee2, Won Taek Lee3, Mi-Sun Hur2, Ho-Jeong Kim2 1Department of Neurology, Gangneung Asan Hospital, University of Ulsan College of Medicine, 2Department of Anatomy, Kwandong University College of Medicine, Gangneung, 3Department of Anatomy, Yonsei University College of Medicine, Seoul, Korea Abstract: Cerebrospinal fluid (CSF) plays an important role in providing brain tissue with a stable internal environment as well as in absorbing mechanical and thermal stresses. From its initial composition, derived from the amniotic fluid trapped by the closure of neuropores, CSF is modified by developing and differentiating ependymal cells lining the ventricular surface or forming the choroid plexus. Its osmolarity and ionic composition brings about a change through the action of many channels expressed on the ependymal cells. Some newly discovered transient receptor potential (TRP) channels are known to be expressed in the choroid plexus ependyma. To detect additional TRP channel expression, immunohistochemical screening was performed at the choroid plexus of 13-, 15-, 17-, and 19-day embryos, using antibodies against TRPV1, TRPV3, and TRPA1, and the expression was compared with those in the adult TRP channels. The level of TRP channel expression was higher in the choroid plexus which suggests more active functioning of TRP channels in the developing choroid plexus than the ventricular lining ependyma in the 15- and 17-day embryos. All the expression of TRP channels decreased at the 19th day of gestation. -
Investigational Drugs in Early Phase Clinical Trials Targeting Thermotransient Receptor Potential (Thermotrp) Channels
Expert Opinion on Investigational Drugs ISSN: (Print) (Online) Journal homepage: https://www.tandfonline.com/loi/ieid20 Investigational drugs in early phase clinical trials targeting thermotransient receptor potential (thermoTRP) channels Asia Fernández-Carvajal , Rosario González-Muñiz , Gregorio Fernández- Ballester & Antonio Ferrer-Montiel To cite this article: Asia Fernández-Carvajal , Rosario González-Muñiz , Gregorio Fernández- Ballester & Antonio Ferrer-Montiel (2020): Investigational drugs in early phase clinical trials targeting thermotransient receptor potential (thermoTRP) channels, Expert Opinion on Investigational Drugs, DOI: 10.1080/13543784.2020.1825680 To link to this article: https://doi.org/10.1080/13543784.2020.1825680 Published online: 29 Sep 2020. Submit your article to this journal Article views: 31 View related articles View Crossmark data Full Terms & Conditions of access and use can be found at https://www.tandfonline.com/action/journalInformation?journalCode=ieid20 EXPERT OPINION ON INVESTIGATIONAL DRUGS https://doi.org/10.1080/13543784.2020.1825680 REVIEW Investigational drugs in early phase clinical trials targeting thermotransient receptor potential (thermoTRP) channels Asia Fernández-Carvajala, Rosario González-Muñizb, Gregorio Fernández-Ballestera and Antonio Ferrer-Montiela aInstituto De Investigación, Desarrollo E Innovación En Biotecnología Sanitaria De Elche (Idibe), Universitas Miguel Hernández, Alicante, Spain; bInstituto De Química Médica, CSIC, Madrid, Spain ABSTRACT ARTICLE HISTORY Introduction: Thermo transient receptor potential (thermoTRP) channels are some of the most inten Received 15 June 2020 sely pursued therapeutic targets of the past decade. They are considered promising targets of numer Accepted 15 September ous diseases including chronic pain and cancer. Modulators of these proteins, in particular TRPV1-4, 2020 TRPM8 and TRPA1, have reached clinical development, but none has been approved for clinical practice KEYWORDS yet. -
TRP CHANNELS AS THERAPEUTIC TARGETS TRP CHANNELS AS THERAPEUTIC TARGETS from Basic Science to Clinical Use
TRP CHANNELS AS THERAPEUTIC TARGETS TRP CHANNELS AS THERAPEUTIC TARGETS From Basic Science to Clinical Use Edited by ARPAD SZALLASI MD, PHD Department of Pathology, Monmouth Medical Center, Long Branch, NJ, USA AMSTERDAM • BOSTON • HEIDELBERG • LONDON NEW YORK • OXFORD • PARIS • SAN DIEGO SAN FRANCISCO • SINGAPORE • SYDNEY • TOKYO Academic Press is an imprint of Elsevier Academic Press is an imprint of Elsevier 125 London Wall, London, EC2Y 5AS, UK 525 B Street, Suite 1800, San Diego, CA 92101-4495, USA 225 Wyman Street, Waltham, MA 02451, USA The Boulevard, Langford Lane, Kidlington, Oxford OX5 1GB, UK First published 2015 Copyright © 2015 Elsevier Inc. All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, or any information storage and retrieval system, without permission in writing from the publisher. Details on how to seek permission, further information about the Publisher’s permissions policies and our arrangement with organizations such as the Copyright Clearance Center and the Copyright Licensing Agency, can be found at our website: www.elsevier.com/permissions This book and the individual contributions contained in it are protected under copyright by the Publisher (other than as may be noted herein). Notices Knowledge and best practice in this field are constantly changing. As new research and experience broaden our understanding, changes in research methods, professional practices, or medical treatment may become necessary. Practitioners and researchers must always rely on their own experience and knowledge in evaluating and using any information, methods, compounds, or experiments described herein. -
Cryo-EM Structure of the Polycystic Kidney Disease-Like Channel PKD2L1
ARTICLE DOI: 10.1038/s41467-018-03606-0 OPEN Cryo-EM structure of the polycystic kidney disease-like channel PKD2L1 Qiang Su1,2,3, Feizhuo Hu1,3,4, Yuxia Liu4,5,6,7, Xiaofei Ge1,2, Changlin Mei8, Shengqiang Yu8, Aiwen Shen8, Qiang Zhou1,3,4,9, Chuangye Yan1,2,3,9, Jianlin Lei 1,2,3, Yanqing Zhang1,2,3,9, Xiaodong Liu2,4,5,6,7 & Tingliang Wang1,3,4,9 PKD2L1, also termed TRPP3 from the TRPP subfamily (polycystic TRP channels), is involved 1234567890():,; in the sour sensation and other pH-dependent processes. PKD2L1 is believed to be a non- selective cation channel that can be regulated by voltage, protons, and calcium. Despite its considerable importance, the molecular mechanisms underlying PKD2L1 regulations are largely unknown. Here, we determine the PKD2L1 atomic structure at 3.38 Å resolution by cryo-electron microscopy, whereby side chains of nearly all residues are assigned. Unlike its ortholog PKD2, the pore helix (PH) and transmembrane segment 6 (S6) of PKD2L1, which are involved in upper and lower-gate opening, adopt an open conformation. Structural comparisons of PKD2L1 with a PKD2-based homologous model indicate that the pore domain dilation is coupled to conformational changes of voltage-sensing domains (VSDs) via a series of π–π interactions, suggesting a potential PKD2L1 gating mechanism. 1 Ministry of Education Key Laboratory of Protein Science, Tsinghua University, Beijing 100084, China. 2 School of Life Sciences, Tsinghua University, Beijing 100084, China. 3 Beijing Advanced Innovation Center for Structural Biology, Tsinghua University, Beijing 100084, China. 4 School of Medicine, Tsinghua University, Beijing 100084, China. -
Snapshot: Mammalian TRP Channels David E
SnapShot: Mammalian TRP Channels David E. Clapham HHMI, Children’s Hospital, Department of Neurobiology, Harvard Medical School, Boston, MA 02115, USA TRP Activators Inhibitors Putative Interacting Proteins Proposed Functions Activation potentiated by PLC pathways Gd, La TRPC4, TRPC5, calmodulin, TRPC3, Homodimer is a purported stretch-sensitive ion channel; form C1 TRPP1, IP3Rs, caveolin-1, PMCA heteromeric ion channels with TRPC4 or TRPC5 in neurons -/- Pheromone receptor mechanism? Calmodulin, IP3R3, Enkurin, TRPC6 TRPC2 mice respond abnormally to urine-based olfactory C2 cues; pheromone sensing 2+ Diacylglycerol, [Ca ]I, activation potentiated BTP2, flufenamate, Gd, La TRPC1, calmodulin, PLCβ, PLCγ, IP3R, Potential role in vasoregulation and airway regulation C3 by PLC pathways RyR, SERCA, caveolin-1, αSNAP, NCX1 La (100 µM), calmidazolium, activation [Ca2+] , 2-APB, niflumic acid, TRPC1, TRPC5, calmodulin, PLCβ, TRPC4-/- mice have abnormalities in endothelial-based vessel C4 i potentiated by PLC pathways DIDS, La (mM) NHERF1, IP3R permeability La (100 µM), activation potentiated by PLC 2-APB, flufenamate, La (mM) TRPC1, TRPC4, calmodulin, PLCβ, No phenotype yet reported in TRPC5-/- mice; potentially C5 pathways, nitric oxide NHERF1/2, ZO-1, IP3R regulates growth cones and neurite extension 2+ Diacylglycerol, [Ca ]I, 20-HETE, activation 2-APB, amiloride, Cd, La, Gd Calmodulin, TRPC3, TRPC7, FKBP12 Missense mutation in human focal segmental glomerulo- C6 potentiated by PLC pathways sclerosis (FSGS); abnormal vasoregulation in TRPC6-/-